MCID: ADS015
MIFTS: 22

Aids Wasting Syndrome

Categories: Blood diseases, Rare diseases

Aliases & Classifications for Aids Wasting Syndrome

MalaCards integrated aliases for Aids Wasting Syndrome:

Name: Aids Wasting Syndrome 58
Hiv Wasting Syndrome 71

Characteristics:

Orphanet epidemiological data:

58
aids wasting syndrome
Prevalence: 1-5/10000 (Europe);

Classifications:

Orphanet: 58  
Rare immunological diseases


External Ids:

ICD10 via Orphanet 33 B22.2
UMLS via Orphanet 72 C0343755
Orphanet 58 ORPHA90081
UMLS 71 C0343755

Summaries for Aids Wasting Syndrome

MalaCards based summary : Aids Wasting Syndrome, also known as hiv wasting syndrome, is related to human immunodeficiency virus type 1 and diarrhea, and has symptoms including cachexia and emaciation. An important gene associated with Aids Wasting Syndrome is CNR1 (Cannabinoid Receptor 1). The drugs Oxandrolone and Hormone Antagonists have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, bone and t cells.

Related Diseases for Aids Wasting Syndrome

Diseases related to Aids Wasting Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 5, show less)
# Related Disease Score Top Affiliating Genes
1 human immunodeficiency virus type 1 10.3
2 diarrhea 10.0
3 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 9.8
4 hypogonadism 9.8
5 muscular atrophy 9.8

Graphical network of the top 20 diseases related to Aids Wasting Syndrome:



Diseases related to Aids Wasting Syndrome

Symptoms & Phenotypes for Aids Wasting Syndrome

UMLS symptoms related to Aids Wasting Syndrome:


cachexia, emaciation

Drugs & Therapeutics for Aids Wasting Syndrome

Drugs for Aids Wasting Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 45, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxandrolone Approved, Investigational Phase 4 53-39-4 5878
2 Hormone Antagonists Phase 4
3 Androgens Phase 4
4 Hormones Phase 4
5 Anabolic Agents Phase 4
6
Testosterone Approved, Experimental, Investigational Phase 2 58-22-0, 481-30-1 10204 6013
7
Megestrol acetate Approved, Investigational, Vet_approved Phase 2 595-33-5 11683
8
Testosterone undecanoate Approved, Investigational Phase 2 5949-44-0
9
Testosterone enanthate Approved Phase 2 315-37-7 9416
10
Methyltestosterone Approved Phase 2 58-18-4 6010
11
Dihydrotestosterone Illicit, Investigational Phase 2 521-18-6 10635
12 Immunologic Factors Phase 2
13 Angiogenesis Inhibitors Phase 2
14 Immunosuppressive Agents Phase 2
15 Anti-Infective Agents Phase 2
16 Anti-Bacterial Agents Phase 2
17 Central Nervous System Stimulants Phase 2
18 Contraceptive Agents Phase 2
19 Contraceptives, Oral Phase 2
20 Antineoplastic Agents, Hormonal Phase 2
21
Megestrol Phase 2 3562-63-8 19090 3080587
22 Testosterone 17 beta-cypionate Phase 2
23
Dronabinol Approved, Illicit Phase 1 1972-08-3 16078
24
Nandrolone decanoate Approved, Illicit Phase 1 360-70-3 9677
25
Nandrolone phenpropionate Approved, Illicit, Investigational Phase 1 62-90-8 229455
26
Nandrolone Experimental, Investigational Phase 1 434-22-0 9904
27 Psychotropic Drugs Phase 1
28 Neurotransmitter Agents Phase 1
29 Analgesics, Non-Narcotic Phase 1
30 Analgesics Phase 1
31 Hallucinogens Phase 1
32
Abacavir Approved, Investigational 136470-78-5 441300 65140
33
Lopinavir Approved 192725-17-0 92727
34
Nevirapine Approved 129618-40-2 4463
35
Ritonavir Approved, Investigational 155213-67-5 392622
36 Pharmaceutical Solutions
37 Anti-HIV Agents
38 Anti-Retroviral Agents
39 Cytochrome P-450 CYP3A Inhibitors
40 Cytochrome P-450 Enzyme Inhibitors
41 Reverse Transcriptase Inhibitors
42
protease inhibitors
43 HIV Protease Inhibitors
44 Antiviral Agents
45 Atazanavir Sulfate

Interventional clinical trials:

(showing 15, show less)
# Name Status NCT ID Phase Drugs
1 Nutrition Intervention in AIDS Wasting Completed NCT00006167 Phase 4 oxandrolone
2 A Randomized, Parallel Group, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of Recombinant Human Growth Hormone (Serostim) in the Treatment of HIV-Associated Catabolism/Wasting Completed NCT00489528 Phase 3 Somatropin; Recombinant human growth hormone (r hGH)
3 AIDS Wasting in Women: Anabolic Effects of Testosterone Completed NCT00006158 Phase 2 Testosterone
4 A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome Completed NCT00002127 Phase 2 Thalidomide
5 Evaluation of High Protein Supplementation in HIV-1-Positive Subjects With Stable Weight Loss Completed NCT00000925 Phase 2 Optimune oral nutritional supplement
6 A Randomized, Open-labeled, Pilot Study Comparing Weight Gain in Adults With AIDS-related Wasting Given Either Megestrol Acetate Oral Suspension Nanocrystal Dispersion (MA-NCD) or Megestrol Acetate Oral Suspension (Megace) Completed NCT00637572 Phase 2 Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL;Megestrol acetate oral suspension 40 mg/mL
7 Double-Blind Randomized Comparison Phase II Trial of Megestrol Acetate and Testosterone Enanthate in Combination Versus Megestrol Acetate Plus Testosterone Enanthate Placebo in Human Immunodeficiency Virus (HIV)-Associated Wasting. Completed NCT00001079 Phase 2 Testosterone enanthate;Megestrol acetate
8 Testosterone and Physical Function in HIV Associate Weight Loss Completed NCT00260143 Phase 2 Testosterone enanthate;Placebo
9 A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome Completed NCT00000737 Phase 1 Dronabinol;Megestrol acetate
10 A Randomized, Double-Blind, Placebo-Controlled, Phase I/II Trial of Nandrolone Decanoate in Women With HIV-Associated Weight Loss Completed NCT00000854 Phase 1 Nandrolone decanoate
11 Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome Completed NCT00002157 Thalidomide
12 Randomized Placebo-Controlled Study of Aerobic Exercise and Resistance Training Plus Megestrol Acetate for HIV-Wasting Completed NCT00004664 megestrol
13 An Open-Label, Randomized, Three-Arm, Comparative Trial of a Caloric Supplement With Peptides and Medium-Chain Triglycerides Versus a Caloric Supplement With Whole Protein and Long-Chain Triglycerides Versus No Caloric Supplement for the Prevention of Weight Loss in Individuals With AIDS Who Take a Daily Multivitamin and Mineral Supplement Completed NCT00001077
14 Effect of Antiretroviral Therapy on Body Composition in HIV-Infected Children Completed NCT00006064
15 A Restrictively Randomized, Open-Label, Controlled, Pilot Study of the Effect of a Thymidine Analogue Substitution or Change to a Nucleoside-Sparing Regimen on Peripheral Fat Wasting Completed NCT00028314 Abacavir sulfate;Atazanavir/Ritonavir;Lopinavir/Ritonavir;Nevirapine

Search NIH Clinical Center for Aids Wasting Syndrome

Genetic Tests for Aids Wasting Syndrome

Anatomical Context for Aids Wasting Syndrome

MalaCards organs/tissues related to Aids Wasting Syndrome:

40
Skeletal Muscle, Bone, T Cells

Publications for Aids Wasting Syndrome

Articles related to Aids Wasting Syndrome:

(showing 116, show less)
# Title Authors PMID Year
1
'Mapping' Health State Utility Values from Non-preference-Based Measures: A Systematic Literature Review in Rare Diseases. 61
32152892 2020
2
Ten-year survival with analysis of gender difference, risk factors, and causes of death during 13 years of public antiretroviral therapy in rural Kenya. 61
32481319 2020
3
Non-obstetric causes of severe maternal complications: a secondary analysis of the Nigeria Near-miss and Maternal Death Survey. 61
30897278 2019
4
Should Oncologists Recommend Cannabis? 61
31161270 2019
5
Are cannabinoids effective for HIV wasting syndrome? 61
29272264 2017
6
AIDS-Defining Illnesses at Initial Diagnosis of HIV in a Large Guatemalan Cohort. 61
29308405 2017
7
[Cannabinoids in palliative care: Systematic review and meta-analysis of efficacy, tolerability and safety]. 61
26809975 2016
8
Clinical utility of dronabinol in the treatment of weight loss associated with HIV and AIDS. 61
26929669 2016
9
Cannabis in cancer care. 61
25777363 2015
10
HIV and/or AIDS-related deaths and modifiable risk factors: A descriptive study of medical admissions at Oshakati Intermediate Hospital in Northern Namibia. 61
26466398 2015
11
Comparative safety evaluation of selective androgen receptor modulators and anabolic androgenic steroids. 61
26401842 2015
12
Legalising medical use of cannabis in South Africa: Is the empirical evidence sufficient to support policy shifts in this direction? 61
25214244 2014
13
Assessment of serum IGF-1 and adipokines related to metabolic dysfunction in HIV-infected adults. 61
23941777 2013
14
Pathophysiology of GHRH-growth hormone-IGF1 axis in HIV/AIDS. 61
23657561 2013
15
Impact of HIV-associated conditions on mortality in people commencing anti-retroviral therapy in resource limited settings. 61
23935870 2013
16
SSI. Man's weight not consistent with HIV wasting syndrome. 61
23476953 2013
17
[Causes of death among 91 HIV-infected adults in the era of potent antiretroviral therapy]. 61
22350063 2012
18
Incidence of WHO stage 3 and 4 conditions following initiation of anti-retroviral therapy in resource limited settings. 61
23284857 2012
19
Human immunodeficiency virus endocrinopathy. 61
22028995 2011
20
Skeletal muscle involvement in human immunodeficiency virus infection: a report of four cases. 61
21150063 2010
21
Therapeutic effects of nandrolone and testosterone in adult male HIV patients with AIDS wasting syndrome (AWS): a randomized, double-blind, placebo-controlled trial. 61
20974577 2010
22
HIV Wasting Syndrome in a Nigerian Failing Antiretroviral Therapy: A Case Report and Review of the Literature. 61
21209738 2010
23
Progressive resistance training in elderly HIV-positive patients: does it work? 61
18925321 2008
24
Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus. 61
18414712 2008
25
Chronic alcohol accentuates simian acquired immunodeficiency syndrome-associated wasting. 61
18028526 2008
26
Interventions for the treatment of decreased bone mineral density associated with HIV infection. 61
17443607 2007
27
Increase in hospital mortality from non-communicable disease and HIV-related conditions in Bulawayo, Zimbabwe, between 1992 and 2000. 61
16884612 2006
28
Reporting and evaluation of HIV-related clinical endpoints in two multicenter international clinical trials. 61
16880169 2006
29
RANTES, MDC and SDF-1alpha, prevent the HIVgp120-induced food and water intake decrease in rats. 61
16343773 2006
30
[Muscular complications of human immunodeficiency virus (HIV) infection in the era of effective anti-retroviral therapy]. 61
16446625 2006
31
HIV/AIDS wasting syndrome in Manipur - a case report. 61
16449850 2005
32
Skeletal muscle involvement in human immunodeficiency virus (HIV)-infected patients in the era of highly active antiretroviral therapy (HAART). 61
15902690 2005
33
[The endogenous cannabinoid system. Therapeutic implications for neurologic and psychiatric disorders]. 61
15776259 2005
34
Increasing risk of 5% or greater unintentional weight loss in a cohort of HIV-infected patients, 1995 to 2003. 61
16123685 2005
35
Use of bioelectrical impedance analysis to determine body composition changes in HIV-associated wasting. 61
15899085 2005
36
Epidemiology of aids defining conditions in Greece. 61
15666458 2004
37
Management of HIV wasting syndrome: a consensus conference. 61
15722868 2004
38
[A novel analgesics made from Cannabis]. 61
15042867 2004
39
Weight loss, wasting, and survival in HIV-positive patients: current strategies. 61
14959696 2003
40
Testosterone replacement for hypogonadism: clinical findings and best practices. 61
14959695 2003
41
Transdermal testosterone for women: a new physiological approach for androgen therapy. 61
12832941 2003
42
AIDS wasting syndrome: trends, influence on opportunistic infections, and survival. 61
12794565 2003
43
Therapeutic potential of cannabinoids in CNS disease. 54
12617697 2003
44
Testosterone therapy in HIV wasting syndrome: systematic review and meta-analysis. 61
12409050 2002
45
HIV wasting syndrome. 61
12084960 2002
46
Thalidomide as an anti-cancer agent. 61
12169202 2002
47
The role of exercise in the prevention and treatment of wasting in acquired immune deficiency syndrome. 61
11828858 2002
48
Metabolic Syndromes Associated With HIV: Mitigating the Side Effects of Drug Therapy. 61
20086559 2001
49
Effects of testosterone and exercise on muscle leanness in eugonadal men with AIDS wasting. 61
11356779 2001
50
Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome. 61
11344201 2001
51
[HIV wasting syndrome]. 61
11555906 2001
52
Differential impact of combined antiretroviral therapy on the survival of italian patients with specific AIDS-defining illnesses. 61
11141245 2000
53
Potential interventions for HIV/AIDS wasting: an overview. 61
11126431 2000
54
Diabetes mellitus associated with recombinant human growth hormone for HIV wasting syndrome. 61
10999508 2000
55
Characteristics of HIV-infected men with low serum testosterone levels. 61
10639065 1999
56
Cutaneous CD8 T cell infiltrates in advanced HIV infection. 61
10534634 1999
57
AIDS-related myopathy. 61
11810429 1999
58
The use of testosterone in the AIDS wasting syndrome. 61
11366208 1999
59
Interleukin-1 alpha (IL-1 alpha) and tumor necrosis factor alpha (TNF alpha) regulate insulin-like growth factor binding protein-1 (IGFBP-1) levels and mRNA abundance in vivo and in vitro. 61
10226804 1999
60
Effects of nandrolone decanoate therapy in borderline hypogonadal men with HIV-associated weight loss. 61
10048900 1999
61
Monitoring changes in fat-free mass in HIV-positive men with hypotestosteronemia and AIDS wasting syndrome treated with gonadal hormone replacement therapy. 61
10202830 1999
62
Effects of androgen administration on the growth hormone-insulin-like growth factor I axis in men with acquired immunodeficiency syndrome wasting. 61
9851759 1998
63
Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. 61
9843994 1998
64
Role of cytokines in AIDS wasting. 61
9834928 1998
65
Global issues in pediatric nutrition: AIDS. 61
9785358 1998
66
Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: a pilot study. 61
9709937 1998
67
Low dihydrotestosterone and weight loss in the AIDS wasting syndrome. 61
9665502 1998
68
Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. 61
9652995 1998
69
Recombinant human growth hormone: old and novel uses. 61
9688021 1998
70
The etiology of wasting in the human immunodeficiency virus and acquired immunodeficiency syndrome. 61
9625388 1998
71
HIV wasting syndrome: treatment update. 61
9562141 1998
72
Analysis of the medical use of marijuana and its societal implications. 61
9654850 1998
73
AIDS wasting syndrome as an enterometabolic disorder: the gut hypothesis. 61
9600025 1998
74
Approaches to the AIDS Wasting Syndrome. 61
11365549 1998
75
Causes of death of HIV-infected persons in Ottawa, Ontario, 1984-1995. 61
9382662 1997
76
NIH conference on AIDS wasting syndrome. National Institutes of Health. 61
11364632 1997
77
Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting. 61
9141512 1997
78
The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative. 61
9071430 1997
79
[Muscular complications in HIV infection]. 61
9382610 1997
80
Influence of age on rates of new AIDS-defining diseases and survival in 6546 AIDS patients. 61
9360246 1997
81
Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. 61
8923860 1996
82
The HIV wasting syndrome. 61
11363990 1996
83
Percutaneous endoscopic gastrostomy in AIDS and control patients: risks and outcome. 61
8792705 1996
84
Unimed Pharmaceuticals begins HIV wasting syndrome trial. 61
11363535 1996
85
[Muscular involvement in HIV infection]. 61
8745623 1995
86
Myopathy and HIV infection. 61
8579969 1995
87
Marijuana, the AIDS wasting syndrome, and the U.S. government. 61
7637743 1995
88
High-dose pentoxifylline in patients with AIDS: inhibition of tumor necrosis factor production. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. 61
7769305 1995
89
Warding off HIV wasting syndrome. 61
10141839 1995
90
Age, gender, and other predictors of the wasting syndrome among HIV-1-infected injecting drug users. 61
7742405 1995
91
Increased tumor necrosis factor-alpha serum levels in patients with HIV wasting syndrome and euthyroid sick syndrome. 61
7834406 1995
92
Pathophysiology and treatment of the AIDS wasting syndrome. 61
7488556 1995
93
Cytokine expression in the muscle of HIV-infected patients: evidence for interleukin-1 alpha accumulation in mitochondria of AZT fibers. 61
7979221 1994
94
The HIV wasting syndrome: a review. 61
8207646 1994
95
Skeletal muscle involvement in HIV-infected patients. 61
7936072 1994
96
Contribution of tuberculosis to slim disease in Africa. 61
7912597 1994
97
Treatment for HIV wasting syndrome. 61
8068997 1994
98
Endocrine function in the HIV wasting syndrome. 61
8263752 1994
99
Differential elevation of circulating interleukin-1 beta, tumor necrosis factor alpha, and interleukin-6 in AIDS-associated cachectic states. 61
7496913 1994
100
Micronutrient concentrations in the HIV wasting syndrome. 61
7904452 1993
101
Survival after AIDS diagnosis in Washington State: trends through 1989 and effect of the case definition change of 1987. 61
8410672 1993
102
Myopathies associated with human immunodeficiency virus and zidovudine: can their effects be distinguished? 61
8492955 1993
103
HIV wasting syndrome in the United States. 61
8466680 1993
104
Effects of increasing outpatient diagnosis on AIDS surveillance. 61
8417181 1993
105
D-xylose malabsorption: characteristic finding in patients with the AIDS wasting syndrome and chronic diarrhea. 61
1453320 1992
106
The HIV wasting syndrome. 61
1501629 1992
107
The slim disease in African patients with AIDS. 61
1412662 1992
108
[AIDS in Germany: clinical manifestations of AIDS]. 61
1545764 1992
109
Pathophysiology of the AIDS wasting syndrome. 61
1606057 1992
110
Orphan drug for HIV wasting syndrome. 61
1950976 1991
111
Clinical management of the complications of HIV infection. 61
2005472 1991
112
Effect of the revised AIDS case definition on AIDS reporting in San Francisco: evidence of increased reporting in intravenous drug users. 61
2350453 1990
113
Human immunodeficiency virus wasting syndrome may represent a treatable myopathy. 61
2314598 1990
114
Zidovudine for treating AIDS. What physicians need to know. 61
2662155 1989
115
Clinical presentations of AIDS and HIV infection in state psychiatric facilities. 61
2656484 1989
116
Potential effect of revising the CDC surveillance case definition for AIDS. 61
2893928 1988

Variations for Aids Wasting Syndrome

Expression for Aids Wasting Syndrome

Search GEO for disease gene expression data for Aids Wasting Syndrome.

Pathways for Aids Wasting Syndrome

GO Terms for Aids Wasting Syndrome

Sources for Aids Wasting Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....